Multiarterial CABG Gets a Boost in Retrospective Analysis

Another retrospective analysis suggests that compared with the standard CABG practice of using the left internal thoracic artery (LITA) supplemented by saphenous vein grafts, multiple arterial grafting is associated with long-term survival and morbidity advantages.

Similar studies in the past have lauded the benefits of the more complex procedure while also highlighting its limited use. But to date, the only randomized prospective trial to address this question—ART—concluded that there was no added benefit of multiarterial grafting versus the conventional single arterial graft over 5 years as well as the potential for increased risk of wound infection in the short term.

ART investigators, who presented the trial results last year at the American Heart Association’s Annual Scientific Sessions, stressed that they still believe the multiarterial strategy, when performed by experienced surgeons, will emerge as the winner long-term.

Now, a new study published online ahead of print in JAMA Cardiology is trying to get at those longer-term outcomes via a population-based, propensity-matched analysis led by Aihua Pu, MSc (Cardiac Services BC, Vancouver, Canada). Pu et al’s data show reduced 15-year mortality following CABG with multiple arterial grafting compared with standard LITA plus vein grafts (HR 0.79; 95% 0.72-0.87) among more than 20,000 adult patients with triple-vessel or left-main disease in British Columbia, Canada. Median follow-up time was 9.1 and 8.1 years for patients receiving multiple and single arterial grafting, respectively.

In addition, multiple arterial grafting was associated with less repeat revascularization (HR 0.74; 95% CI 0.66-0.84) over 15 years plus lower risk of MI (HR 0.63; 95% CI 0.47-0.85) and heart failure (HR 0.79; 95% CI 0.64-0.98) over 7 years compared with single arterial grafting. These results were maintained across a wide variety of patient subgroups.

On the other hand, while there were no differences in 30-day outcomes between the study arms, patients who received multiarterial grafting were more likely to require sternal reconstruction over 180 days than those who received LITA plus vein grafts (RR 1.76; 95% CI 1.10-2.81).

Notably, of the 5,580 study participants who received multiarterial grafting, the right internal thoracic artery was used after the LITA in just over half of the patients and the radial artery was used in the rest. Also, the proportion of women in the multiarterial grafting group was almost half of those in the LITA plus vein grafts cohort (10.5% vs 19.3%).

“The long-term benefits consistently observed across multiple outcomes and subgroups support the consideration of [multiple arterial grafting] for a broader spectrum of patients who are undergoing [CABG] in routine practice,” the authors write.

Awaiting ART

Commenting on the study, Frank Sellke, MD (Brown University, Providence, RI), told TCTMD that while it shows “what most of us believe—that there is benefit from multiarterial grafting,” the implications of this analysis are limited given the patient population. He pointed to the substantial baseline differences between the study groups such as patient sex as well as ejection fraction, history of heart failure, peripheral vascular disease, COPD, and moderate/severe anemia. Given those differences and what researchers already know from previous studies, patients in the LITA plus vein grafts arm could be expected to have worse outcomes regardless of the type of CABG they received, he said.

“Now, they did a lot of fancy statistical tests, but I think this demonstrates some of the shortcomings of using retrospective propensity analysis,” Sellke observed. Additionally, these studies cannot shed any light on unexamined factors like bypass graft quality, calcification, and patient compliance and frailty, even though these constraints have “major impacts on outcomes after heart surgery.”

Operators tend to use multiple arterial grafts only when patients have a long life expectancy, Sellke said, adding that only about 10% of US patients receive this kind of CABG. The reasons for this, he explained, are the lack of hard data showing a benefit with it over standard single-artery grafting as well as the fact that completing multiple grafts is “somewhat inconvenient.

“I hate to say that, but it takes some effort to take both mammary arteries down or the mammary artery and the radial artery, or both of those. It adds time to the operation. If there’s not that much perceived benefit, a lot of surgeons simply don't do it,” Sellke said.

The ART trial investigators are planning to follow their patients out to 10 years, with results from that time point expected within the next couple of years, he noted. If those “show a clear benefit, [multiarterial grafting] will catch on to a much greater extent.” For now, Sellke acknowledged, while “there are strong advocates for multiple arterial grafting, . . . we’re just going to continue doing things the way we're doing them until we have convincing evidence otherwise.”